Korean Stock Flows

Dong Kook Pharmaceutical (KRX: 086450)

동국제약 KOSDAQ Biotech & Pharma 의약품 제조업
Close (Oct 16, 2026)
₩25,300
+2.43%
Market cap
₩1T ($0.9B)
52-week range
₩16,260 – ₩31,250
P/E (12M fwd) · P/B · Div yield
12.43 · 1.72 · 0.79%
trailing 17.01 · consensus of 1 analysts

Who is buying Dong Kook Pharmaceutical?

Between Sep 15, 2026 and Oct 16, 2026 (20 trading sessions), foreign investors net sold ₩18.6bn ($14M) of Dong Kook Pharmaceutical, the 30th largest foreign net sale among 1828 KOSDAQ stocks. Institutions net bought ₩41.9bn ($31M) and retail investors net sold ₩27.2bn ($20M) over the same window. Foreigners were net buyers on 7 of the 20 sessions.

Foreign investors hold 9.5% of Dong Kook Pharmaceutical's listed shares (KRX ownership data as of Oct 16, 2026), down from 10.81% twenty sessions earlier and 13.96% a year ago.

The stock closed at ₩25,300 on Oct 16, 2026: +23.41% over 20 sessions, +47.52% year-to-date, +33.58% over one year. The 52-week range is ₩16,260 – ₩31,250.

At ₩25,300 the stock trades at 12.43× 12-month-forward consensus earnings (1 analysts), 12.15× on FY2027 estimates. The trailing P/E published by KRX is 17.01×, based on the last completed fiscal year.

Dong Kook Pharmaceutical share price, last 60 trading days (KRW)
25,796 22,712 19,628 16,544 Jul 16 Aug 31 Oct 16
Daily foreign investor net purchases, last 60 trading days
+11.3bn +5.6bn -5.6bn -11.3bn Jul 16 Aug 31 Oct 16
View chart data as a table
Date Close Foreign net Institutions Retail
2026-10-16 ₩25,300 +₩0.8bn +₩0.9bn ₩-2.1bn
2026-10-15 ₩24,700 ₩-0.7bn +₩3.8bn ₩-3.3bn
2026-10-14 ₩24,250 ₩-0.9bn +₩4.1bn ₩-3.8bn
2026-10-13 ₩23,250 ₩-1.7bn +₩2.2bn ₩-0.4bn
2026-10-12 ₩23,600 +₩0.4bn +₩3.5bn ₩-5.2bn
2026-10-08 ₩22,400 ₩-1.8bn +₩1.3bn +₩0.7bn
2026-10-07 ₩22,700 +₩0.7bn +₩1.9bn ₩-4.3bn
2026-10-06 ₩21,700 ₩-5.0bn +₩0.5bn +₩4.4bn
2026-10-02 ₩22,750 ₩-6.0bn +₩6.5bn ₩-0.5bn
2026-10-01 ₩22,150 ₩-0.9bn +₩1.2bn ₩-0.1bn
2026-09-30 ₩21,500 ₩-2.1bn +₩3.0bn ₩-1.1bn
2026-09-29 ₩21,400 +₩0.2bn +₩1.8bn ₩-2.1bn
2026-09-28 ₩21,050 ₩-1.7bn +₩0.2bn +₩1.4bn
2026-09-23 ₩21,350 +₩4.2bn +₩1.9bn ₩-6.0bn
2026-09-22 ₩20,500 +₩0.0bn +₩0.4bn ₩-0.4bn
2026-09-21 ₩21,100 +₩0.2bn +₩1.1bn ₩-1.2bn
2026-09-18 ₩20,650 ₩-0.6bn +₩1.1bn ₩-0.8bn
2026-09-17 ₩21,100 ₩-1.0bn +₩1.7bn ₩-0.6bn
2026-09-16 ₩20,850 ₩-1.4bn +₩2.4bn ₩-0.9bn
2026-09-15 ₩20,300 ₩-1.4bn +₩2.4bn ₩-1.0bn
2026-09-14 ₩20,500 ₩-1.3bn +₩3.1bn ₩-1.8bn
2026-09-11 ₩19,850 ₩-1.0bn +₩0.6bn +₩0.2bn
2026-09-10 ₩19,620 ₩-0.8bn +₩0.7bn +₩0.1bn
2026-09-09 ₩19,740 +₩0.3bn ₩-0.2bn ₩-0.0bn
2026-09-08 ₩19,930 +₩1.5bn ₩-1.6bn +₩0.3bn
2026-09-07 ₩20,800 ₩-0.8bn +₩1.1bn +₩0.1bn
2026-09-04 ₩21,600 ₩-3.5bn +₩1.1bn +₩1.8bn
2026-09-03 ₩21,800 ₩-5.1bn +₩4.9bn +₩0.3bn
2026-09-02 ₩21,850 ₩-4.6bn +₩4.3bn +₩0.2bn
2026-09-01 ₩21,900 ₩-4.6bn +₩3.9bn +₩0.5bn
2026-08-31 ₩22,250 ₩-11.3bn +₩2.0bn +₩8.6bn
2026-08-28 ₩21,500 +₩5.9bn +₩4.8bn ₩-9.7bn
2026-08-27 ₩18,640 ₩-3.0bn ₩-0.5bn +₩3.4bn
2026-08-26 ₩19,200 ₩-0.9bn +₩1.3bn ₩-0.2bn
2026-08-25 ₩18,850 ₩-2.3bn ₩-0.2bn +₩2.6bn
2026-08-24 ₩19,210 +₩2.9bn +₩1.7bn ₩-4.8bn
2026-08-21 ₩17,770 ₩-3.3bn ₩-1.1bn +₩4.3bn
2026-08-20 ₩18,500 ₩-0.2bn +₩0.2bn ₩-0.0bn
2026-08-19 ₩18,000 ₩-2.8bn +₩1.2bn +₩1.4bn
2026-08-18 ₩18,200 ₩-4.6bn ₩-0.7bn +₩5.1bn
2026-08-14 ₩19,720 ₩-0.3bn ₩-1.0bn +₩2.0bn
2026-08-13 ₩20,450 ₩-1.2bn +₩0.1bn +₩1.1bn
2026-08-12 ₩21,600 ₩-4.5bn +₩2.8bn +₩1.7bn
2026-08-11 ₩21,450 +₩3.3bn +₩1.4bn ₩-4.5bn
2026-08-10 ₩20,100 +₩0.6bn +₩0.6bn ₩-1.0bn
2026-08-07 ₩19,300 +₩0.1bn +₩0.1bn ₩-0.1bn
2026-08-06 ₩19,200 +₩1.4bn +₩0.2bn ₩-1.5bn
2026-08-05 ₩18,320 +₩0.1bn ₩-0.3bn +₩0.3bn
2026-08-04 ₩18,230 +₩0.8bn ₩-0.6bn ₩-0.2bn
2026-08-03 ₩17,570 +₩0.1bn ₩-0.3bn +₩0.2bn
2026-07-31 ₩17,500 ₩-0.5bn ₩-0.6bn +₩1.1bn
2026-07-30 ₩17,140 +₩0.4bn +₩0.1bn ₩-0.5bn
2026-07-29 ₩17,040 +₩1.2bn ₩-0.2bn ₩-1.0bn
2026-07-28 ₩17,460 +₩0.6bn ₩-0.9bn +₩0.1bn
2026-07-27 ₩18,580 +₩0.2bn +₩0.3bn ₩-0.5bn
2026-07-24 ₩18,230 +₩1.0bn ₩-0.7bn ₩-0.3bn
2026-07-23 ₩18,570 +₩0.8bn ₩-1.3bn +₩0.4bn
2026-07-22 ₩18,200 ₩-2.0bn +₩0.1bn +₩1.0bn
2026-07-21 ₩18,820 ₩-0.3bn +₩0.5bn ₩-0.4bn
2026-07-20 ₩18,350 ₩-1.6bn +₩0.7bn +₩0.6bn
2026-07-16 ₩19,290 ₩-0.8bn +₩1.1bn ₩-0.3bn

Investor flows summary

Window Foreign (USD) Institutions Retail
1 day +₩0.8bn +$1M +₩0.9bn ₩-2.1bn
5 days ₩-2.1bn $-2M +₩14.6bn ₩-14.7bn
20 days ₩-18.6bn $-14M +₩41.9bn ₩-27.2bn

Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.

Frequently asked questions

Are foreign investors buying Dong Kook Pharmaceutical stock?

Over the last 5 sessions foreign investors net sold ₩2.1bn ($2M) of Dong Kook Pharmaceutical; over 60 sessions they net sold ₩57.7bn ($43M); since Jan 1, 2026 they net sold ₩61.7bn ($46M). Over 20 sessions the stock is the 30th largest foreign net sale among 1828 KOSDAQ stocks.

How much of Dong Kook Pharmaceutical do foreign investors own?

Foreign investors own 9.5% of Dong Kook Pharmaceutical's shares as of Oct 16, 2026, versus 13.96% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.

Who is on the other side — institutions or retail investors?

Over 20 sessions institutions net bought ₩41.9bn ($31M) and retail investors net sold ₩27.2bn ($20M) of Dong Kook Pharmaceutical. Institutions are on the other side of foreign selling.

Is Dong Kook Pharmaceutical listed on KOSPI or KOSDAQ?

Dong Kook Pharmaceutical (동국제약) trades on KOSDAQ under KRX code 086450 in the Biotech & Pharma group, with a market capitalization of ₩1T ($0.9B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.

Annual financials

Fiscal year Revenue YoY Operating profit Net income
2023 ₩731bn ($543M) – ₩67bn ($50M) ₩49bn ($36M)
2024 ₩812bn ($603M) +11.10% ₩80bn ($60M) ₩62bn ($46M)
2025 ₩927bn ($689M) +14.10% ₩97bn ($72M) ₩74bn ($55M)

Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1345.9/$) for reference only.

← All foreign investor flows